BioCentury | Sep 18, 2006
Company News

Duravest management update

Duravest Inc. (DUVT; FSE:DUV), Chicago, Ill. Business: Cardiovascular Hired: Hendrik Hammje as interim CEO, formerly an investment banker at Altium Capital Ltd.; he replaces Ogan Gurel, who resigned WIR Staff Cardiovascular...
BioCentury | Sep 18, 2006
Company News

Duravest board of directors update

Duravest Inc. (DUVT; FSE:DUV), Chicago, Ill. Business: Cardiovascular Appointed: Hans-Albert Kolb, head of the Institute for Biophysics, dean of the faculty of biology and a board member at the University of Hannover, as chairman; he...
BioCentury | Oct 31, 2005
Clinical News

17beta-estradiol: Phase II data

...TVF) in the high-dose 17beta-estradiol group, although the results were not statistically significant vs. placebo. Duravest...
...both TVF and TLR. Data were presented at the Canadian Cardiovascular Congress meeting in Montreal. Duravest Inc....
BioCentury | Sep 12, 2005
Company News

Duravest board of directors update

Duravest Inc. (DUVT), Toronto, Ontario Business: Drug delivery Appointed: Fredrich Goebel, CEO and senior partner of Viscardi AG WIR Staff...
BioCentury | Sep 12, 2005
Company News

Duravest management update

Duravest Inc. (DUVT), Toronto, Ontario Business: Drug delivery Hired: Ogan Gurel as president and CEO, formerly VP and medical director at Sg2 WIR Staff...
BioCentury | Jul 25, 2005
Company News

MediVas LCC, Duravest deal

...treat coronary heart disease. Financial terms were not disclosed. MediVas LCC , San Diego, Calif. Duravest Inc....
Items per page:
1 - 6 of 6
BioCentury | Sep 18, 2006
Company News

Duravest management update

Duravest Inc. (DUVT; FSE:DUV), Chicago, Ill. Business: Cardiovascular Hired: Hendrik Hammje as interim CEO, formerly an investment banker at Altium Capital Ltd.; he replaces Ogan Gurel, who resigned WIR Staff Cardiovascular...
BioCentury | Sep 18, 2006
Company News

Duravest board of directors update

Duravest Inc. (DUVT; FSE:DUV), Chicago, Ill. Business: Cardiovascular Appointed: Hans-Albert Kolb, head of the Institute for Biophysics, dean of the faculty of biology and a board member at the University of Hannover, as chairman; he...
BioCentury | Oct 31, 2005
Clinical News

17beta-estradiol: Phase II data

...TVF) in the high-dose 17beta-estradiol group, although the results were not statistically significant vs. placebo. Duravest...
...both TVF and TLR. Data were presented at the Canadian Cardiovascular Congress meeting in Montreal. Duravest Inc....
BioCentury | Sep 12, 2005
Company News

Duravest board of directors update

Duravest Inc. (DUVT), Toronto, Ontario Business: Drug delivery Appointed: Fredrich Goebel, CEO and senior partner of Viscardi AG WIR Staff...
BioCentury | Sep 12, 2005
Company News

Duravest management update

Duravest Inc. (DUVT), Toronto, Ontario Business: Drug delivery Hired: Ogan Gurel as president and CEO, formerly VP and medical director at Sg2 WIR Staff...
BioCentury | Jul 25, 2005
Company News

MediVas LCC, Duravest deal

...treat coronary heart disease. Financial terms were not disclosed. MediVas LCC , San Diego, Calif. Duravest Inc....
Items per page:
1 - 6 of 6